170 related articles for article (PubMed ID: 32945468)
1. A novel HDAC1 inhibitor, CBUD‑1001, exerts anticancer effects by modulating the apoptosis and EMT of colorectal cancer cells.
Kim SL; La MT; Shin MW; Kim SW; Kim HK
Int J Oncol; 2020 Oct; 57(4):1027-1038. PubMed ID: 32945468
[TBL] [Abstract][Full Text] [Related]
2. A novel HDAC1/2 inhibitor suppresses colorectal cancer through apoptosis induction and cell cycle regulation.
Lee HY; Tang DW; Liu CY; Cho EC
Chem Biol Interact; 2022 Jan; 352():109778. PubMed ID: 34929181
[TBL] [Abstract][Full Text] [Related]
3. A novel class I HDAC inhibitor, MPT0G030, induces cell apoptosis and differentiation in human colorectal cancer cells via HDAC1/PKCδ and E-cadherin.
Wang LT; Liou JP; Li YH; Liu YM; Pan SL; Teng CM
Oncotarget; 2014 Jul; 5(14):5651-62. PubMed ID: 25015091
[TBL] [Abstract][Full Text] [Related]
4. Discovery of quinazolinyl-containing benzamides derivatives as novel HDAC1 inhibitors with in vitro and in vivo antitumor activities.
Zhang Z; Zhang Q; Zhang H; Jiao M; Guo Z; Peng X; Fu L; Li J
Bioorg Chem; 2021 Dec; 117():105407. PubMed ID: 34653945
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel coumarin-based benzamides as potent histone deacetylase inhibitors and anticancer agents.
Abdizadeh T; Kalani MR; Abnous K; Tayarani-Najaran Z; Khashyarmanesh BZ; Abdizadeh R; Ghodsi R; Hadizadeh F
Eur J Med Chem; 2017 May; 132():42-62. PubMed ID: 28340413
[TBL] [Abstract][Full Text] [Related]
6. Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.
Yang F; Shan P; Zhao N; Ge D; Zhu K; Jiang CS; Li P; Zhang H
Bioorg Med Chem Lett; 2019 Jan; 29(1):15-21. PubMed ID: 30455152
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells.
Zhijun H; Shusheng W; Han M; Jianping L; Li-Sen Q; Dechun L
Tumour Biol; 2016 Aug; 37(8):10257-67. PubMed ID: 26831668
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and evaluation of Cd[L-proline]
Chidambaram A; Sekar A; S H K; Chidambaram RK; Arunachalam K; G P S; Vilwanathan R
Invest New Drugs; 2017 Dec; 35(6):691-705. PubMed ID: 28776290
[TBL] [Abstract][Full Text] [Related]
9. Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.
Li X; Zhang Y; Jiang Y; Wu J; Inks ES; Chou CJ; Gao S; Hou J; Ding Q; Li J; Wang X; Huang Y; Xu W
Eur J Med Chem; 2017 Jul; 134():185-206. PubMed ID: 28415009
[TBL] [Abstract][Full Text] [Related]
10. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells.
Kiweler N; Brill B; Wirth M; Breuksch I; Laguna T; Dietrich C; Strand S; Schneider G; Groner B; Butter F; Heinzel T; Brenner W; Krämer OH
Arch Toxicol; 2018 Jul; 92(7):2227-2243. PubMed ID: 29845424
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors.
Yuan Z; Sun Q; Li D; Miao S; Chen S; Song L; Gao C; Chen Y; Tan C; Jiang Y
Eur J Med Chem; 2017 Jul; 134():281-292. PubMed ID: 28419930
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms underlying the antitumor activity of (E)-N-hydroxy-3-(1-(4-methoxyphenylsulfonyl)-1,2,3,4-tetrahydroquinolin-6-yl)acrylamide in human colorectal cancer cells in vitro and in vivo.
Chen CH; Lee CH; Liou JP; Teng CM; Pan SL
Oncotarget; 2015 Nov; 6(34):35991-6002. PubMed ID: 26462017
[TBL] [Abstract][Full Text] [Related]
13. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells.
Flis S; Gnyszka A; Flis K; Spławiński J
Eur J Pharmacol; 2010 Feb; 627(1-3):26-32. PubMed ID: 19853597
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
Yang F; Zhao N; Song J; Zhu K; Jiang CS; Shan P; Zhang H
Molecules; 2019 Jul; 24(14):. PubMed ID: 31311163
[TBL] [Abstract][Full Text] [Related]
15. Anticancer Study of a Novel Pan-HDAC Inhibitor MPT0G236 in Colorectal Cancer Cells.
Tsai FL; Huang HL; Lai MJ; Liou JP; Pan SL; Yang CR
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628767
[TBL] [Abstract][Full Text] [Related]
16. Targeting the E2F1/Rb/HDAC1 axis with the small molecule HR488B effectively inhibits colorectal cancer growth.
Duan N; Hu X; Qiu H; Zhou R; Li Y; Lu W; Zhu Y; Shen S; Wu W; Yang F; Liu N
Cell Death Dis; 2023 Dec; 14(12):801. PubMed ID: 38062013
[TBL] [Abstract][Full Text] [Related]
17. A novel class I histone deacetylase inhibitor, I-7ab, induces apoptosis and arrests cell cycle progression in human colorectal cancer cells.
Yang L; Liang Q; Shen K; Ma L; An N; Deng W; Fei Z; Liu J
Biomed Pharmacother; 2015 Apr; 71():70-8. PubMed ID: 25960218
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitors, MS275 and SBHA, enhances cytotoxicity induced by oxaliplatin in the colorectal cancer cell lines.
Flis S; Gnyszka A; Spławiński J
Biochem Biophys Res Commun; 2009 Sep; 387(2):336-41. PubMed ID: 19596269
[TBL] [Abstract][Full Text] [Related]
19. The HDAC1 Inhibitor CBUD-1001 Enhances TRAIL-induced Apoptosis in Colorectal Cancer Cells.
Shin MW; Kim SL; Yang HC; Yim SK; Seo SY; Lee ST; Kim HK; Kim SW
Anticancer Res; 2021 Sep; 41(9):4353-4364. PubMed ID: 34475055
[TBL] [Abstract][Full Text] [Related]
20. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition.
Singh A; Chang TY; Kaur N; Hsu KC; Yen Y; Lin TE; Lai MJ; Lee SB; Liou JP
Eur J Med Chem; 2021 Apr; 215():113169. PubMed ID: 33588178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
